Skip to content

Pilot Study of Prenatal Choline Supplementation

A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development: Pilot Arm for Non-Drinking Women

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07699393
Enrollment
50
Registered
2026-07-13
Start date
2026-07-08
Completion date
2028-05-15
Last updated
2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Development, Choline Nutrition

Keywords

Choline, Prenatal nutrition, dietary supplementation

Brief summary

A double-blind, randomized, placebo-controlled trial (RCT; NCT04395196) of prenatal choline supplementation is ongoing (1) to assess the effectiveness of maternal choline supplementation during pregnancy to mitigate effects of PAE on three primary outcomes: infant recognition memory and postnatal growth restriction (weight and head circumference); (2) to assess the efficacy of this supplementation for mitigating alcohol effects on the following secondary outcomes: infant eyeblink conditioning, postnatal length, and information processing speed. The study design was based on a pilot feasibility study in 70 heavy-drinking pregnant women. Infants in the choline-treated arm were more likely to meet criterion for eyeblink conditioning than those in the placebo arm. Infants born to both the choline- and placebo-treated mothers were small at birth, but those in the choline arm showed considerable catch-up growth in weight and head circumference by 6.5 months, which persisted through 12 months. At 12 months, infants in the choline arm showed markedly better recognition memory compared to placebo-treated on the Fagan Test of Infant Intelligence, which is known to have predictive validity for school-age IQ. Of note, infants with heavy prenatal alcohol exposure whose mothers were in the active choline treatment arm performed better on FTII novelty preference neurobehavioral testing than infants in an observational study that was running in parallel who had no prenatal alcohol exposure. These pilot findings indicate that any beneficial effects of prenatal choline supplementation seen may be due in part or entirely due to general beneficial effects on fetal brain development rather than mechanisms that are specific to the teratogenic effects of alcohol. Thus, the aim of this pilot study is to enroll and randomize 50 alcohol-abstaining pregnant women to participate in an identical study protocol (same study procedures and primary and secondary outcomes) to NCT04395196, which includes only alcohol-consuming pregnant women. Effect sizes between this pilot, non-drinking group and the larger study of alcohol-consuming women will be compared to explore the degree to which prenatal choline supplementation benefits growth and neurobehavior in infants without prenatal alcohol exposure and to explore the degree to which beneficial treatment effects of choline are specific to prenatal alcohol exposure.

Detailed description

The study protocol will be identical to NCT04395196 except for sample size (goal = 50 pregnant women and their infants) and that instead of including heavy-drinking pregnant women, inclusion criteria require that women have fully abstained from alcohol during pregnancy at the time of randomization. All other inclusion/exclusion criteria and study procedures are identical.

Interventions

DIETARY_SUPPLEMENTPlacebo

Provided in beverage form

DIETARY_SUPPLEMENTCholine bitartrate

Provided in beverage form.

Sponsors

Wayne State University
Lead SponsorOTHER
Columbia University
CollaboratorOTHER
University of Cape Town
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Age ≥18 yr * ≤20 wk gestation * Singleton pregnancy * Abstinence from alcohol since conception (by report) * Current choline dietary intake \<1 g/day * Language fluency in English or Afrikaans

Exclusion criteria

* Use of methamphetamine or other illicit drugs other than marijuana during the past year * HIV positive * Pharmacologic treatment for a serious pre-existing medical condition (e.g., diabetes, hypertension, epilepsy, or cardiac problems) * Having another child enrolled in the trial from a previous pregnancy * Plans for mother or child to move away from the area prior to study completion

Design outcomes

Primary

MeasureTime frameDescription
Infant recognition memory12 monthsNovelty preference from the Fagan Test of Infant Intelligence
Postnatal infant weight gain6.5 months
Postnatal growth in infant head circumference6.5 months

Secondary

MeasureTime frameDescription
Infant information processing speed12 monthsProcessing speed on the Fagan Test of Infant Intelligence
Postnatal growth in infant length6.5 months

Countries

South Africa

Contacts

CONTACTR. Colin Carter, MD, MMSc
rcc2142@cumc.columbia.edu+12123052995
CONTACTSandra W Jacobson, PhD
sandra.jacobson@wayne.edu+13139935454
PRINCIPAL_INVESTIGATORR. Colin Carter, MD, MMSc

Columbia University

PRINCIPAL_INVESTIGATORSandra W Jacobson, PhD

Wayne State University

PRINCIPAL_INVESTIGATORJoseph L Jacobson, PhD

Wayne State University

PRINCIPAL_INVESTIGATORErnesta M Meinjtes, PhD

University of Cape Town

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026